What Do FTC’s Aggressive Moves Against Biopharma Portend For 2024?

 
• By Brenda Sandburg
FTC statue - pink perspectives
US Federal Trade Commission derailed or restricted several transactions last year. • Source: Shutterstock

More from Compliance

More from Pink Sheet